English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169226
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications

AuthorsMorado, Morado; Sandes, Alex F.; Colado, Enrique; Subirá, Dolores; Isusi, Paloma; Noya, María Soledad; Vidriales, Maria Belén; Sempere, Amparo; Díaz, José Ángel; Minguela, Alfredo; Álvarez, Beatriz; Serrano, Cristina ; Caballero-Velázquez, Teresa; Rey, Mercedes; Pérez Corral, Ana; Fernández Jiménez, María Crsitina; Magro, Elena; Lemes, Angelina; Benavente, Cecilia; Bañas, Helena; Merino, Juana; Castejon, Celine; Gutierrez, Olivier; Rabasa, Pilar; Vescovi Gonçalves, Matheus; Pérez-Andrés, Martin; Orfao, Alberto
Myelodysplastic syndrome
Flow cytometry
Fluorescence cytometry
Issue Date2017
PublisherJohn Wiley & Sons
CitationCytometry Part B: Clinical Cytometry 92(5): 361-370 (2017)
Abstract[Background]: Although consensus guidelines have been proposed in 2010 for the diagnostic screening of paroxysmal nocturnal hemoglobinuria (PNH) by flow cytometry (FCM), so far no study has investigated the efficiency of such medical indications in multicentric vs. reference laboratory settings. [Methods]: Here we evaluate the efficiency of consensus medical indications for PNH testing in 3,938 peripheral blood samples submitted to FCM testing in 24 laboratories in Spain and one reference center in Brazil. [Results]: Overall, diagnostic screening based on consensus medical indications was highly efficient (14% of PNH samples) both in the multicenter setting in Spain (10%) and the reference laboratory in Brazil (16%). The highest frequency of PNH cases was observed among patients screened because of bone marrow (BM) failure syndrome (33%), particularly among those with aplastic anemia (AA; 45%) and to a less extent also a myelodysplastic syndrome (MDS; 10%). Among the other individuals studied, the most efficient medical indications for PNH screening included: hemolytic anemia (19%), hemoglobinuria (48%) and unexplained cytopenias (9%). In contrast, only a minor fraction of the patients who had been submitted for PNH testing because of unexplained thrombosis in the absence of cytopenia, were positive (0.4%). [Conclusions]: In summary, our results demonstrate that the current medical indications for PNH screening by FCM are highly efficient, although improved screening algorithms are needed for patients presenting with thrombosis and normal blood cell counts.
DescriptionOn behalf of the PNH working group of the Iberian Society of Cytometry (SIC).
Identifiersdoi: 10.1002/cyto.b.21480
e-issn: 1552-4957
issn: 1552-4949
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.